ibuprofen has been researched along with Infant, Premature, Diseases in 96 studies
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine
Infant, Premature, Diseases: Diseases that occur in PREMATURE INFANTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Recently, we gave L-lysine ibuprofen to a preterm infant with respiratory distress to induce closure of a patent ductus arteriosus, and the infant experienced pulmonary hypertension." | 7.73 | Pulmonary hypertension following L-lysine ibuprofen therapy in a preterm infant with patent ductus arteriosus. ( Bellini, C; Campone, F; Serra, G, 2006) |
| "Presence of symptomatic patent ductus arteriosus is common in small preterm infants and ibuprofen is commonly used for its medical closure." | 5.39 | Pulmonary hypertension in an infant treated with ibuprofen. ( Kumarshingri, PS; Sehgal, A, 2013) |
| "Course of sepsis was evaluated by CRP and IL-6 levels." | 5.38 | The effects of ibuprofen on sepsis parameters in preterm neonates. ( Canpolat, FE; Celik, IH; Demirel, G; Dilmen, U; Erdeve, O; Oguz, SS, 2012) |
| "Pulmonary hypertension is a rare but potentially fatal complication of ibuprofen administration in preterm infants." | 5.38 | Severe pulmonary hypertension with therapeutic L-lysine ibuprofen in 2 preterm neonates. ( Aghai, ZH; Amendolia, B; Bhat, V; Lynn, M; Ritz, SB, 2012) |
| "This study aims to determine whether or not treatment of preterm neonates with PDA using IV ibuprofen can impair renal function and in what range of birth weights and gestational ages the risk of major renal side-effects due to ibuprofen is highest." | 5.17 | Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. ( Bagnoli, F; Casucci, M; Messina, G; Mori, A; Rossetti, A; Tomasini, B, 2013) |
| "Ibuprofen therapy on the third day of life is as efficacious as indomethacin for the treatment of patent ductus arteriosus in preterm infants with the respiratory distress syndrome and is significantly less likely to induce oliguria." | 5.09 | A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. ( Degroote, K; Langhendries, JP; Lecoutere, D; Smets, K; Van de Broek, H; Van Overmeire, B; Weyler, J, 2000) |
| "Gastrointestinal complications observed in infants treated with ibuprofen for PDA including gastrointestinal perforations occur in less mature infants." | 3.96 | Adverse events related to ibuprofen treatment for patent ductus arteriosus in premature neonates. ( Berthiller, J; Bouamari, H; Claris, O; Ndour, D; Nguyen, KA; Plaisant, F, 2020) |
| "Hypertension during pregnancy, even without intrauterine growth restriction, appeared to carry the same risk for MRB as exposure to ibuprofen and extrauterine growth restriction." | 3.79 | Risk factors of mild rectal bleeding in very low birth weight infants: a case control study. ( Ben Said, M; Hays, S; Jordan, I; Maucort-Boulch, D; Oulmaati, A; Picaud, JC, 2013) |
| "To compare the incidence of medical closure of patent ductus arteriosus (PDA) and adverse events (acute renal dysfunction, necrotizing enterocolitis, spontaneous intestinal perforation, and gastrointestinal bleeding) between preterm infants who received indomethacin and ibuprofen for the treatment of PDA." | 3.79 | Effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus in preterm infants. ( Bali, V; Harabor, A; Kamaluddeen, M; Sivanandan, S; Soraisham, AS, 2013) |
| "A prospective study with subjects serving as their own controls was performed on <30 weeks' gestational age infants with unconjugated hyperbilirubinemia and who received ibuprofen for patent ductus arteriosus." | 3.77 | Effect of ibuprofen on bilirubin-albumin binding affinity in premature infants. ( Amin, SB; Miravalle, N, 2011) |
| " Recently, we gave L-lysine ibuprofen to a preterm infant with respiratory distress to induce closure of a patent ductus arteriosus, and the infant experienced pulmonary hypertension." | 3.73 | Pulmonary hypertension following L-lysine ibuprofen therapy in a preterm infant with patent ductus arteriosus. ( Bellini, C; Campone, F; Serra, G, 2006) |
| "The question of whether to treat patent ductus arteriosus (PDA) early or wait until symptoms appear remains high on the research agenda for neonatal medicine." | 3.01 | Study protocol: baby-OSCAR trial: Outcome after Selective early treatment for Closure of patent ductus ARteriosus in preterm babies, a multicentre, masked, randomised placebo-controlled parallel group trial. ( Bell, JL; Edwards, C; Field, D; Gupta, S; Hardy, P; Hutchison, E; Johnson, S; Juszczak, E; Kelsall, W; Laube, M; Linsell, L; Pepperell, J; Roberts, T; Sinha, S; Stanbury, K; Subhedar, N; Wyllie, J, 2021) |
| "Echocardiographically guided ibuprofen treatment of patent ductus arteriosus is feasible and reduces unnecessary doses of medication." | 2.79 | Randomised controlled clinical trial of standard versus echocardiographically guided ibuprofen treatment for patent ductus arteriosus in preterm infants: a pilot study. ( Bravo, MC; Cabañas, F; Pellicer, A; Pérez-Fernández, E; Pérez-Rodríguez, J; Quero, J; Riera, J, 2014) |
| " Target concentration approach by the evaluation of trough level may be applicable to real-time dosing strategy." | 2.78 | The relationship between trough drug concentrations and ductal closure in preterm infants treated with three-dose-oral ibuprofen. ( Dilmen, U; Erdeve, O; Oncel, MY; Ozdemir, R; Yurttutan, S, 2013) |
| "Ibuprofen levels were detectable 1 h after administration, peaked after 8 h and remained in a relative plateau until 24 h postadministration." | 2.77 | Pharmacokinetics of oral ibuprofen for patent ductus arteriosus closure in preterm infants. ( Baram, S; Barzilay, B; Batash, D; Berkovitch, M; Goldman, M; Heyman, E; Keidar, R; Youngster, I, 2012) |
| "Ibuprofen treatment had no effect on TB, UB, or Ka values." | 2.77 | Unbound bilirubin does not increase during ibuprofen treatment of patent ductus arteriosus in preterm infants. ( Barbier, A; Bordarier, C; Desfrere, L; Kibleur, Y; Moriette, G; Thibaut, C, 2012) |
| "Ibuprofen treatment within the first 5 days of life was indicated when at least two out of four conventional echocardiography criteria were observed: ductal diameter >2 mm, left-right ductal shunt maximum velocity <2 m/sec, mean flow velocity in left pulmonary artery >0." | 2.77 | Echocardiography as a guide for patent ductus arteriosus ibuprofen treatment and efficacy prediction. ( Boubred, F; Desandes, E; Desandes, R; Haddad, F; Hascoët, JM; Jellimann, JM; Rouabah, M; Semama, DS; Vieux, R, 2012) |
| "Indomethacin is widely accepted as the treatment for patent ductus arteriosus (PDA) in preterm infants but it has various side effects." | 2.71 | A comparison of oral ibuprofen and intravenous indomethacin for closure of patent ductus arteriosus in preterm infants. ( Chotigeat, U; Jirapapa, K; Layangkool, T, 2003) |
| "59 liters/kg), but the median serum half-life (16." | 2.71 | Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life. ( Allegaert, K; Cossey, V; Devlieger, H; Langhendries, JP; Naulaers, G; Van Overmeire, B; Vanhole, C, 2004) |
| "The occurrence of patent ductus arteriosus was less frequent only on day 3 of life in the ibuprofen group." | 2.71 | Prophylactic ibuprofen for the prevention of intraventricular hemorrhage among preterm infants: a multicenter, randomized study. ( Bertini, G; Dani, C; Guerrini, P; Martano, C; Pezzati, M; Poggi, C; Rubaltelli, FF, 2005) |
| "Ibuprofen has recently been shown to be effective in closing PDA with fewer hemodynamic effects." | 2.71 | [Ibuprofen versus indomethacin in the treatment of patent ductus arteriosus in preterm infants]. ( Cano Sánchez, A; Carrasco Moreno, JI; Fernández Gilino, C; Gimeno Navarro, A; Gutiérrez Laso, A; Izquierdo Macián, I; Morcillo Sopena, F, 2005) |
| "Ibuprofen treatment significantly reduced plasma levels of prostaglandins, and the levels remained low for 72 hours in newborns who received three doses of the drug." | 2.68 | Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. ( Aranda, JV; Bardin, CL; Beharry, K; Chemtob, S; Papageorgiou, A; Varvarigou, A, 1996) |
| ""Patent ductus arteriosus is one of most common problems that physicians caring for preterm infants have to face." | 2.47 | Patent ductus arteriosus: wait and see? ( Ciarmoli, E; Mosca, F; Schena, F, 2011) |
| "The persistence of a patent ductus arteriosus (PDA) in preterm infants complicates their clinical course and may contribute to increased morbidity." | 2.46 | Efficacy and tolerability of enteral formulations of ibuprofen in the treatment of patent ductus arteriosus in preterm infants. ( Gouyon, JB; Kibleur, Y, 2010) |
| "Indomethacin has long been the drug of choice." | 2.45 | Therapeutic closure of the ductus arteriosus: benefits and limitations. ( Boubred, F; Mercanti, I; Simeoni, U, 2009) |
| " The drug has prolonged elimination (plasma half-life = ca 23 hours), suggesting that once daily dosing is appropriate." | 2.43 | Systematic review: intravenous Ibuprofen in preterm newborns. ( Aranda, JV; Thomas, R, 2006) |
| "To describe the diagnosis and treatment of patent ductus arteriosus (PDA) in infants born at <32 weeks' gestational age (GA) in England and Wales between 2010 and 2017." | 1.72 | Management of patent ductus arteriosus in very preterm infants in England and Wales: a retrospective cohort study. ( Al-Turkait, A; Choonara, I; Ojha, S; Szatkowski, L, 2022) |
| "Patent ductus arteriosus is a common problem frequently encountered in preterm infants." | 1.48 | Reopening of the ductus arteriosus in preterm infants; Clinical aspects and subsequent consequences. ( Atay, FY; Buyuktiryaki, M; Halil, H; Oncel, MY; Uras, N, 2018) |
| " All four participating neonatal ICU had a comparable number of preterm infants; however, differences were observed in the incidence of treatment (33-63%), choice and dosing of medication (ibuprofen or indomethacin), number of pharmacological courses (1-4), and the need for surgical ligation after failure of pharmacological treatment (8-52%)." | 1.46 | Using benchmarking to identify inter-centre differences in persistent ductus arteriosus treatment: can we improve outcome? ( Andriessen, P; de Boode, WP; de Vries, WB; Dijkman, KP; Jansen, EJS; van Lingen, RA; Vijlbrief, DC, 2017) |
| "And ibuprofen treatment did not negatively influence renal and mesenteric oxygenation and extraction in infants with PDA (p > 0." | 1.40 | Renal and mesenteric tissue oxygenation in preterm infants treated with oral ibuprofen. ( Altug, N; Dilmen, U; Guzoglu, N; Oguz, SS; Ozdemir, R; Sari, FN; Uras, N, 2014) |
| "Presence of symptomatic patent ductus arteriosus is common in small preterm infants and ibuprofen is commonly used for its medical closure." | 1.39 | Pulmonary hypertension in an infant treated with ibuprofen. ( Kumarshingri, PS; Sehgal, A, 2013) |
| "The effect of patent ductus arteriosus (PDA) treatment with cyclooxygenase (COX) inhibitors (indomethacin [INDO] and ibuprofen [IBU]) on regional oxygenation requires further clarification." | 1.38 | Does treatment of patent ductus arteriosus with cyclooxygenase inhibitors affect neonatal regional tissue oxygenation? ( Bhatt, M; Mehta, R; Petrova, A, 2012) |
| "Pulmonary hypertension is a rare but potentially fatal complication of ibuprofen administration in preterm infants." | 1.38 | Severe pulmonary hypertension with therapeutic L-lysine ibuprofen in 2 preterm neonates. ( Aghai, ZH; Amendolia, B; Bhat, V; Lynn, M; Ritz, SB, 2012) |
| "Course of sepsis was evaluated by CRP and IL-6 levels." | 1.38 | The effects of ibuprofen on sepsis parameters in preterm neonates. ( Canpolat, FE; Celik, IH; Demirel, G; Dilmen, U; Erdeve, O; Oguz, SS, 2012) |
| "In ibuprofen group, there was no correlation of AQP2 level with urinary osmolality." | 1.37 | Urinary aquaporin-2 excretion during ibuprofen or indomethacin treatment in preterm infants with patent ductus arteriosus. ( Aperia, A; Casper, C; Li, Y; Marcoux, MO; Plat-Willson, G; Zelenina, M, 2011) |
| "Ibuprofen treatment caused a significant decrease in urinary AVP (UAVP/Ucr 24." | 1.33 | Urinary ET-1, AVP and sodium in premature infants treated with indomethacin and ibuprofen for patent ductus arteriosus. ( Faggian, D; Favaro, F; Lago, P; Plebani, M; Trevisanuto, D; Vedovato, S; Zanardo, V, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (5.21) | 18.2507 |
| 2000's | 30 (31.25) | 29.6817 |
| 2010's | 52 (54.17) | 24.3611 |
| 2020's | 9 (9.38) | 2.80 |
| Authors | Studies |
|---|---|
| Martini, S | 1 |
| Vitali, F | 1 |
| Capelli, I | 1 |
| Donadei, C | 1 |
| Raschi, E | 1 |
| Aiello, V | 1 |
| Corvaglia, L | 1 |
| De Ponti, F | 1 |
| Poluzzi, E | 1 |
| Galletti, S | 1 |
| Al-Turkait, A | 1 |
| Szatkowski, L | 1 |
| Choonara, I | 1 |
| Ojha, S | 1 |
| Höck, M | 1 |
| Sappler, M | 1 |
| Hammerl, M | 1 |
| Griesmaier, E | 1 |
| Ndayisaba, JP | 1 |
| Schreiner, C | 1 |
| Pupp-Peglow, U | 1 |
| Kiechl-Kohlendorfer, U | 1 |
| Neubauer, V | 1 |
| Carneiro, L | 1 |
| Bouissou, A | 1 |
| Favrais, G | 1 |
| Ndour, D | 1 |
| Bouamari, H | 1 |
| Berthiller, J | 1 |
| Claris, O | 1 |
| Plaisant, F | 1 |
| Nguyen, KA | 1 |
| El-Khuffash, A | 1 |
| Bussmann, N | 1 |
| Breatnach, CR | 1 |
| Smith, A | 1 |
| Tully, E | 1 |
| Griffin, J | 1 |
| McCallion, N | 1 |
| Corcoran, JD | 1 |
| Fernandez, E | 1 |
| Looi, C | 1 |
| Cleary, B | 1 |
| Franklin, O | 1 |
| McNamara, PJ | 1 |
| Gupta, S | 1 |
| Juszczak, E | 1 |
| Hardy, P | 1 |
| Subhedar, N | 1 |
| Wyllie, J | 1 |
| Kelsall, W | 1 |
| Sinha, S | 1 |
| Johnson, S | 1 |
| Roberts, T | 1 |
| Hutchison, E | 1 |
| Pepperell, J | 1 |
| Linsell, L | 1 |
| Bell, JL | 1 |
| Stanbury, K | 1 |
| Laube, M | 1 |
| Edwards, C | 1 |
| Field, D | 1 |
| Yurttutan, S | 3 |
| Gullu, UU | 1 |
| Samiee-Zafarghandy, S | 1 |
| van Donge, T | 1 |
| Fusch, G | 1 |
| Pfister, M | 1 |
| Jacob, G | 1 |
| Atkinson, A | 1 |
| Rieder, MJ | 1 |
| Smit, C | 1 |
| Van Den Anker, J | 1 |
| Jansen, EJS | 1 |
| Dijkman, KP | 2 |
| van Lingen, RA | 1 |
| de Vries, WB | 1 |
| Vijlbrief, DC | 2 |
| de Boode, WP | 2 |
| Andriessen, P | 1 |
| Huang, X | 1 |
| Wang, F | 1 |
| Wang, K | 1 |
| El-Farrash, RA | 1 |
| El Shimy, MS | 1 |
| El-Sakka, AS | 1 |
| Ahmed, MG | 1 |
| Abdel-Moez, DG | 1 |
| Hundscheid, T | 1 |
| Onland, W | 1 |
| van Overmeire, B | 4 |
| Dijk, P | 1 |
| van Kaam, AHLC | 1 |
| Kooi, EMW | 1 |
| Villamor, E | 1 |
| Kroon, AA | 1 |
| Visser, R | 1 |
| de Tollenaer, SM | 1 |
| Cools, F | 1 |
| van Laere, D | 1 |
| Johansson, AB | 1 |
| Hocq, C | 1 |
| Zecic, A | 1 |
| Adang, E | 1 |
| Donders, R | 1 |
| de Vries, W | 1 |
| van Heijst, AFJ | 1 |
| Halil, H | 1 |
| Buyuktiryaki, M | 2 |
| Atay, FY | 1 |
| Oncel, MY | 3 |
| Uras, N | 4 |
| Olsson, KW | 1 |
| Larsson, A | 1 |
| Jonzon, A | 1 |
| Sindelar, R | 1 |
| Kaur, S | 1 |
| Stritzke, A | 1 |
| Soraisham, AS | 2 |
| Guler Kazanci, E | 1 |
| Unsal, H | 1 |
| Tayman, C | 1 |
| Sallmon, H | 1 |
| Aydin, T | 1 |
| Hort, S | 1 |
| Kubinski, A | 1 |
| Bode, C | 1 |
| Klippstein, T | 1 |
| Endesfelder, S | 1 |
| Bührer, C | 1 |
| Koehne, P | 1 |
| Erdeve, O | 4 |
| Ozdemir, R | 3 |
| Dilmen, U | 5 |
| Guzoglu, N | 1 |
| Sari, FN | 1 |
| Oguz, SS | 3 |
| Altug, N | 3 |
| Bravo, MC | 1 |
| Cabañas, F | 2 |
| Riera, J | 1 |
| Pérez-Fernández, E | 1 |
| Quero, J | 1 |
| Pérez-Rodríguez, J | 1 |
| Pellicer, A | 2 |
| Oulmaati, A | 1 |
| Hays, S | 1 |
| Ben Said, M | 1 |
| Maucort-Boulch, D | 1 |
| Jordan, I | 1 |
| Picaud, JC | 1 |
| Coceani, F | 1 |
| ElHassan, NO | 1 |
| Bird, TM | 1 |
| King, AJ | 1 |
| Ambadwar, PB | 1 |
| Jaquiss, RD | 1 |
| Kaiser, JR | 1 |
| Robbins, JM | 1 |
| Lu, D | 1 |
| Liu, Y | 1 |
| Tong, X | 1 |
| Bourgoin, L | 1 |
| Cipierre, C | 1 |
| Hauet, Q | 1 |
| Basset, H | 1 |
| Gournay, V | 1 |
| Rozé, JC | 1 |
| Flamant, C | 1 |
| Gascoin, G | 1 |
| Vettukattil, JJ | 1 |
| Haw, MP | 1 |
| Kalani, M | 1 |
| Shariat, M | 1 |
| Khalesi, N | 1 |
| Farahani, Z | 1 |
| Ahmadi, S | 1 |
| Zanardo, V | 2 |
| Vedovato, S | 2 |
| Chiozza, L | 1 |
| Faggian, D | 2 |
| Favaro, F | 2 |
| Trevisanuto, D | 2 |
| Pereira-da-Silva, L | 1 |
| Pita, A | 1 |
| Virella, D | 1 |
| Serelha, M | 1 |
| Golombek, SG | 1 |
| Sola, A | 1 |
| Baquero, H | 1 |
| Borbonet, D | 1 |
| Fajardo, C | 1 |
| Goldsmit, G | 1 |
| Lemus, L | 1 |
| Miura, E | 1 |
| Pérez, JM | 1 |
| Rogido, M | 1 |
| Zambosco, G | 1 |
| Zecca, E | 1 |
| Romagnoli, C | 2 |
| De Carolis, MP | 2 |
| Costa, S | 1 |
| Marra, R | 1 |
| De Luca, D | 1 |
| Richards, J | 1 |
| Johnson, A | 1 |
| Fox, G | 1 |
| Campbell, M | 1 |
| Mercanti, I | 1 |
| Boubred, F | 2 |
| Simeoni, U | 1 |
| Aranda, JV | 3 |
| Beharry, KD | 1 |
| Valencia, GB | 1 |
| Benitz, WE | 1 |
| Jones, LJ | 1 |
| Craven, PD | 1 |
| Attia, J | 1 |
| Thakkinstian, A | 1 |
| Wright, I | 1 |
| Longini, M | 1 |
| Perrone, S | 1 |
| Vezzosi, P | 1 |
| Proietti, F | 1 |
| Marzocchi, B | 1 |
| Buonocore, G | 1 |
| Fanos, V | 2 |
| Antonucci, R | 1 |
| Brunoldi, E | 1 |
| Amin, SB | 1 |
| Miravalle, N | 1 |
| Bagnoli, F | 2 |
| Rossetti, A | 2 |
| Casucci, M | 2 |
| Mori, A | 2 |
| Gokmen, T | 1 |
| Li, Y | 1 |
| Zelenina, M | 1 |
| Plat-Willson, G | 1 |
| Marcoux, MO | 1 |
| Aperia, A | 1 |
| Casper, C | 1 |
| Gouyon, JB | 1 |
| Kibleur, Y | 2 |
| Brissaud, O | 1 |
| Guichoux, J | 1 |
| Desandes, R | 1 |
| Jellimann, JM | 1 |
| Rouabah, M | 1 |
| Haddad, F | 1 |
| Desandes, E | 1 |
| Semama, DS | 1 |
| Vieux, R | 1 |
| Hascoët, JM | 1 |
| Thibaut, C | 2 |
| Hazard, A | 1 |
| Huon, C | 1 |
| Desfrere, L | 3 |
| Dani, C | 3 |
| Schena, F | 1 |
| Ciarmoli, E | 1 |
| Mosca, F | 4 |
| Barzilay, B | 1 |
| Youngster, I | 1 |
| Batash, D | 1 |
| Keidar, R | 1 |
| Baram, S | 1 |
| Goldman, M | 1 |
| Berkovitch, M | 1 |
| Heyman, E | 1 |
| Demirel, G | 1 |
| Celik, IH | 1 |
| Canpolat, FE | 1 |
| Barbier, A | 1 |
| Bordarier, C | 1 |
| Moriette, G | 2 |
| Bersani, I | 1 |
| De Rosa, G | 1 |
| Cota, F | 1 |
| Roberts, C | 1 |
| Berrington, J | 1 |
| Embleton, N | 1 |
| Dhami, S | 1 |
| Amitai, Y | 1 |
| Hammerman, C | 2 |
| Pusceddu, M | 1 |
| Dessì, A | 1 |
| Marcialis, MA | 1 |
| Adrouche-Amrani, L | 1 |
| Green, RS | 1 |
| Gluck, KM | 1 |
| Lin, J | 1 |
| Bin-Nun, A | 1 |
| Kaplan, M | 1 |
| Bhatt, M | 1 |
| Petrova, A | 1 |
| Mehta, R | 1 |
| Amendolia, B | 1 |
| Lynn, M | 1 |
| Bhat, V | 1 |
| Ritz, SB | 1 |
| Aghai, ZH | 1 |
| El-Khuffash, AF | 1 |
| Mertens, L | 1 |
| Ekmen, S | 1 |
| Sehgal, A | 1 |
| Kumarshingri, PS | 1 |
| van der Lugt, NM | 1 |
| Lopriore, E | 1 |
| Bökenkamp, R | 1 |
| Smits-Wintjens, VE | 1 |
| Steggerda, SJ | 1 |
| Walther, FJ | 1 |
| Messina, G | 1 |
| Tomasini, B | 1 |
| Zhang, CC | 1 |
| Cheng, GQ | 1 |
| Sivanandan, S | 1 |
| Bali, V | 1 |
| Harabor, A | 1 |
| Kamaluddeen, M | 1 |
| Schmidt, B | 1 |
| Wright, LL | 1 |
| Davis, P | 1 |
| Solimano, A | 1 |
| Roberts, RS | 1 |
| Bray, M | 3 |
| Stucchi, I | 1 |
| Fumagalli, M | 3 |
| Supapannachart, S | 1 |
| Limrungsikul, A | 1 |
| Khowsathit, P | 1 |
| Morley, GM | 1 |
| Su, PH | 1 |
| Chen, JY | 1 |
| Su, CM | 1 |
| Huang, TC | 1 |
| Lee, HS | 1 |
| Chotigeat, U | 1 |
| Jirapapa, K | 1 |
| Layangkool, T | 1 |
| Allegaert, K | 1 |
| Cossey, V | 1 |
| Langhendries, JP | 2 |
| Naulaers, G | 1 |
| Vanhole, C | 1 |
| Devlieger, H | 1 |
| Distefano, G | 1 |
| Zohar, S | 1 |
| Morville, P | 1 |
| Brunhes, A | 1 |
| Chevret, S | 1 |
| Pons, G | 1 |
| Rey, E | 1 |
| Treluyer, JM | 1 |
| Bertini, G | 2 |
| Pezzati, M | 2 |
| Poggi, C | 1 |
| Guerrini, P | 1 |
| Martano, C | 1 |
| Rubaltelli, FF | 2 |
| Lago, P | 1 |
| Plebani, M | 1 |
| Gimeno Navarro, A | 1 |
| Cano Sánchez, A | 1 |
| Fernández Gilino, C | 1 |
| Carrasco Moreno, JI | 1 |
| Izquierdo Macián, I | 1 |
| Gutiérrez Laso, A | 1 |
| Morcillo Sopena, F | 1 |
| Jaillard, S | 1 |
| Larrue, B | 1 |
| Rakza, T | 1 |
| Magnenant, E | 1 |
| Warembourg, H | 1 |
| Storme, L | 1 |
| Bellini, C | 1 |
| Campone, F | 1 |
| Serra, G | 1 |
| Thomas, R | 1 |
| Vanhaesebrouck, S | 1 |
| Zonnenberg, I | 1 |
| Vandervoort, P | 1 |
| Bruneel, E | 1 |
| Van Hoestenberghe, MR | 1 |
| Theyskens, C | 1 |
| Cherif, A | 1 |
| Jabnoun, S | 1 |
| Khrouf, N | 1 |
| Su, BH | 1 |
| Lin, HC | 1 |
| Chiu, HY | 1 |
| Hsieh, HY | 1 |
| Chen, HH | 1 |
| Tsai, YC | 1 |
| van den Anker, JN | 1 |
| Patel, J | 1 |
| Marks, KA | 1 |
| Roberts, I | 1 |
| Azzopardi, D | 1 |
| Edwards, AD | 1 |
| Varvarigou, A | 1 |
| Bardin, CL | 1 |
| Beharry, K | 1 |
| Chemtob, S | 1 |
| Papageorgiou, A | 1 |
| Lattanzio, M | 1 |
| Tosetto, C | 1 |
| Colnaghi, MR | 1 |
| Compagnoni, G | 1 |
| Vangi, V | 1 |
| Biagiotti, R | 1 |
| Cianciulli, D | 1 |
| Smets, K | 1 |
| Lecoutere, D | 1 |
| Van de Broek, H | 1 |
| Weyler, J | 1 |
| Degroote, K | 1 |
| Clyman, RI | 1 |
| Casalaz, D | 1 |
| Drukker, A | 1 |
| Guignard, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Drug Utilization Patterns in Neonatal Units in the UK: a Retrospective Pharmaco-epidemiological Study[NCT03773289] | 642,729 participants (Actual) | Observational | 2018-04-20 | Completed | |||
| Comparison Between the Effect of Oral Paracetamol Versus Oral Ibuprofen in the Treatment of Patent Ductus Arteriosus in Preterm and Low Birth Weight Infants[NCT03265782] | Phase 4 | 30 participants (Actual) | Interventional | 2015-06-30 | Active, not recruiting | ||
| Multi-center, Randomized Non-inferiority Trial of Early Treatment Versus Expectative Management of Patent Ductus Arteriosus in Preterm Infants (BeNeDuctus Trial - Belgium Netherlands Ductus Trial)[NCT02884219] | 273 participants (Actual) | Interventional | 2016-12-23 | Completed | |||
| The Best Treatment Strategy: Surgical Versus Pharmacological, to Close the Ductus Arteriosus Persistent in Preterm Infants. A Randomized Controlled Trial[NCT02602054] | Phase 2 | 40 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| Combination of Acetaminophen and Ibuprofen in the Management of Patent Ductus Arteriosus in Premature Infants: A Pilot Study[NCT03103022] | Phase 1 | 20 participants (Actual) | Interventional | 2017-06-12 | Completed | ||
| Comparison of the Efficacy of IV Acetaminophen Versus IV Indomethacin in Treatment of Hemodynamically Significant PDA in VLBW Infants[NCT03537144] | Phase 3 | 37 participants (Actual) | Interventional | 2016-06-30 | Terminated (stopped due to Difficulty enrolling patients) | ||
| Oral Ibuprofen Prophylaxis for Patent Ductus Arterioses in Very Extremely Low Birth Weight Infants[NCT01400737] | 200 participants (Anticipated) | Interventional | 2011-07-31 | Recruiting | |||
| Ibuprofen and Renal Function in Premature Infants[NCT00217191] | Phase 4 | 120 participants | Interventional | 2004-09-30 | Completed | ||
| Liberal Versus Restrictive Platelet Transfusion for Treatment of Hemodynamically Significant Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates- A Randomized Open Label, Controlled Trial[NCT03022253] | Phase 3 | 44 participants (Anticipated) | Interventional | 2016-03-31 | Completed | ||
| Paracetamol (Acetaminophen) for Closure of PDA in Preterm Infants[NCT01755728] | Phase 3 | 19 participants (Actual) | Interventional | 2013-01-01 | Completed | ||
| Paracetamol Versus Ibuprofen for Patent Ductus Arteriosus Closure in Preterm Infants. A Prospective, Randomized, Controlled, Double Blind, Multicenter Clinical Trial.[NCT02056223] | Phase 2/Phase 3 | 120 participants (Anticipated) | Interventional | 2017-01-09 | Suspended (stopped due to We enrolled only 53 patients) | ||
| Randomized Pilot Study Comparing Oral Ibuprofen With Intravenous Ibuprofen in Very Low Birth Weight Infants With Patent Ductus Arteriosus[NCT00642330] | Phase 4 | 62 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Long Term Follow-up of the TREOCAPA (Prophylactic TREatment Of the duCtus Arteriosus in Preterm Infants by Acetaminophen) Study (TREOCAPA-LT)[NCT06064825] | 500 participants (Anticipated) | Observational | 2023-11-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
17 reviews available for ibuprofen and Infant, Premature, Diseases
| Article | Year |
|---|---|
Paracetamol versus ibuprofen for the treatment of patent ductus arteriosus in preterm neonates: a meta-analysis of randomized controlled trials.
Topics: Acetaminophen; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Infant, Newborn; Infant, Premat | 2018 |
Therapeutic manipulation of the ductus arteriosus: current options and future prospects.
Topics: Ductus Arteriosus, Patent; Female; Forecasting; Hemodynamics; Humans; Ibuprofen; Indomethacin; Infan | 2014 |
Surgical Intervention in Preterm Neonates with Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Combined Modality Therapy; Cyclooxygenase Inhibitors; Ductus Arteriosus, | 2016 |
Therapeutic closure of the ductus arteriosus: benefits and limitations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Evidence-Based Medicine; Gestati | 2009 |
Nonsteroidal anti-inflammatory drugs (NSAIDs) in the newborn - which ones?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Hemorrhage; Humans; Ibuprofen; I | 2009 |
Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiac Surgical Procedures; Confidence Intervals; Ductus A | 2010 |
Network meta-analysis of indomethacin versus ibuprofen versus placebo for PDA in preterm infants.
Topics: Cardiovascular Agents; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprof | 2011 |
Efficacy and tolerability of enteral formulations of ibuprofen in the treatment of patent ductus arteriosus in preterm infants.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Ductus Arte | 2010 |
Effect of ibuprofen on bilirubin-albumin binding during the treatment of patent ductus arteriosus in preterm infant.
Topics: Albumins; Anti-Inflammatory Agents, Non-Steroidal; Bilirubin; Ductus Arteriosus, Patent; Humans; Ibu | 2011 |
New therapeutic strategies for the treatment of patent ductus arteriosus in preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newbo | 2011 |
Patent ductus arteriosus: wait and see?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; | 2011 |
Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns?
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Extre | 2011 |
Managing the patent ductus arteriosus in the premature neonate: a new look at what we thought we knew.
Topics: Acetaminophen; Biomarkers; Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Echocardiogr | 2012 |
[Progresses in treatment of patent ductus arteriosus in premature infants].
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Wei | 2012 |
[The pharmacological manipulation of Botallo's duct in the duct-dependent congenital cardiopathies and in the preterm infants with respiratory distress. A review and personal findings].
Topics: Alprostadil; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Agents; Cerebral Angiography; C | 2005 |
Systematic review: intravenous Ibuprofen in preterm newborns.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indom | 2006 |
Use of ibuprofen in paediatric populations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chickenpox; Child; Fever; Humans; Ibuprofen; Infant, Newbor | 2007 |
26 trials available for ibuprofen and Infant, Premature, Diseases
| Article | Year |
|---|---|
A Pilot Randomized Controlled Trial of Early Targeted Patent Ductus Arteriosus Treatment Using a Risk Based Severity Score (The PDA RCT).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Infan | 2021 |
Study protocol: baby-OSCAR trial: Outcome after Selective early treatment for Closure of patent ductus ARteriosus in preterm babies, a multicentre, masked, randomised placebo-controlled parallel group trial.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant; Infant, Low Birth | 2021 |
Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial.
Topics: Acetaminophen; Administration, Oral; Case-Control Studies; Double-Blind Method; Ductus Arteriosus, P | 2019 |
Early treatment versus expectative management of patent ductus arteriosus in preterm infants: a multicentre, randomised, non-inferiority trial in Europe (BeNeDuctus trial).
Topics: Cost-Benefit Analysis; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Enterocolitis, Necrotiz | 2018 |
The relationship between trough drug concentrations and ductal closure in preterm infants treated with three-dose-oral ibuprofen.
Topics: Administration, Oral; Birth Weight; Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Fem | 2013 |
Randomised controlled clinical trial of standard versus echocardiographically guided ibuprofen treatment for patent ductus arteriosus in preterm infants: a pilot study.
Topics: Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Echocardiography; Female; Gestational A | 2014 |
A Comparison of Early Ibuprofen and Indomethacin Administration to Prevent Intraventricular Hemorrhage Among Preterm Infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Cyclooxygenase Inhibitors; Ductus Arte | 2016 |
Pharmacological closure of patent ductus arteriosus: effects on pulse pressure and on endothelin-1 and vasopressin excretion.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arginine Vasopressin; Blood Pressure; Ductus Arteriosus, Pa | 2008 |
Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus.
Topics: Administration, Oral; Bilirubin; Cyclooxygenase Inhibitors; Cystatin C; Ductus Arteriosus, Patent; E | 2011 |
Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus.
Topics: Administration, Oral; Bilirubin; Cyclooxygenase Inhibitors; Cystatin C; Ductus Arteriosus, Patent; E | 2011 |
Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus.
Topics: Administration, Oral; Bilirubin; Cyclooxygenase Inhibitors; Cystatin C; Ductus Arteriosus, Patent; E | 2011 |
Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus.
Topics: Administration, Oral; Bilirubin; Cyclooxygenase Inhibitors; Cystatin C; Ductus Arteriosus, Patent; E | 2011 |
Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus.
Topics: Administration, Oral; Bilirubin; Cyclooxygenase Inhibitors; Cystatin C; Ductus Arteriosus, Patent; E | 2011 |
Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus.
Topics: Administration, Oral; Bilirubin; Cyclooxygenase Inhibitors; Cystatin C; Ductus Arteriosus, Patent; E | 2011 |
Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus.
Topics: Administration, Oral; Bilirubin; Cyclooxygenase Inhibitors; Cystatin C; Ductus Arteriosus, Patent; E | 2011 |
Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus.
Topics: Administration, Oral; Bilirubin; Cyclooxygenase Inhibitors; Cystatin C; Ductus Arteriosus, Patent; E | 2011 |
Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus.
Topics: Administration, Oral; Bilirubin; Cyclooxygenase Inhibitors; Cystatin C; Ductus Arteriosus, Patent; E | 2011 |
Echocardiography as a guide for patent ductus arteriosus ibuprofen treatment and efficacy prediction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Drug Administration Schedule; Ductus Arteri | 2012 |
Pharmacokinetics of oral ibuprofen for patent ductus arteriosus closure in preterm infants.
Topics: Administration, Oral; Birth Weight; Cyclooxygenase Inhibitors; Drug Administration Schedule; Ductus | 2012 |
Unbound bilirubin does not increase during ibuprofen treatment of patent ductus arteriosus in preterm infants.
Topics: Albumins; Bilirubin; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Ductus Arteriosus, | 2012 |
Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns.
Topics: Birth Weight; Blood Urea Nitrogen; Creatinine; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; | 2013 |
Ibuprofen prophylaxis in preterm neonates.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Hypertension, Pulmonary; Hypoxia; Ibup | 2002 |
Oral ibuprofen and indomethacin for treatment of patent ductus arteriosus in premature infants: a randomized trial at Ramathibodi Hospital.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Hu | 2002 |
Comparison of ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Femal | 2003 |
A comparison of oral ibuprofen and intravenous indomethacin for closure of patent ductus arteriosus in preterm infants.
Topics: Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofe | 2003 |
Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life.
Topics: Amikacin; Bacterial Infections; Double-Blind Method; Gestational Age; Half-Life; Humans; Ibuprofen; | 2004 |
Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method.
Topics: Bayes Theorem; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Double-Blind Met | 2005 |
Prophylactic ibuprofen for the prevention of intraventricular hemorrhage among preterm infants: a multicenter, randomized study.
Topics: Cerebral Hemorrhage; Cerebral Ventricles; Cerebrovascular Circulation; Double-Blind Method; Ductus A | 2005 |
[Ibuprofen versus indomethacin in the treatment of patent ductus arteriosus in preterm infants].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indom | 2005 |
Comparison of ibuprofen and indometacin for early-targeted treatment of patent ductus arteriosus in extremely premature infants: a randomised controlled trial.
Topics: Analysis of Variance; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Ductus Arteriosus | 2008 |
Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants.
Topics: Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Ductus Arteriosu | 1996 |
Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus.
Topics: Blood Flow Velocity; Brain; Cerebrovascular Circulation; Cyclooxygenase Inhibitors; Dose-Response Re | 1997 |
Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newbo | 1999 |
A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newbo | 2000 |
53 other studies available for ibuprofen and Infant, Premature, Diseases
| Article | Year |
|---|---|
Impact of nephrotoxic drugs on urinary biomarkers of renal function in very preterm infants.
Topics: Acute Kidney Injury; Amikacin; Biomarkers; Female; Humans; Ibuprofen; Infant; Infant, Newborn; Infan | 2022 |
Management of patent ductus arteriosus in very preterm infants in England and Wales: a retrospective cohort study.
Topics: Ductus Arteriosus, Patent; Female; Fetal Growth Retardation; Humans; Ibuprofen; Indomethacin; Infant | 2022 |
Prophylactic low-dose paracetamol for ductal closure and neurodevelopmental outcome in very preterm infants.
Topics: Acetaminophen; Child; Child, Preschool; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant; Infant | 2023 |
Increasing the dose of ibuprofen with postnatal age to close a hemodynamically significant patent ductus arteriosus in very preterm infants.
Topics: Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Infant, Newborn; Infant, Premature; Infant, Pr | 2023 |
Adverse events related to ibuprofen treatment for patent ductus arteriosus in premature neonates.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Ibuprofen; In | 2020 |
The Effect of Dual (Combined) Treatment in Late Preterm Infants with Patent Ductus Arteriosus.
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant; Infant, Newborn; Infant, Pr | 2022 |
Novel strategy to personalise use of ibuprofen for closure of patent ductus arteriosus in preterm neonates.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Drug Monitoring; Du | 2022 |
Using benchmarking to identify inter-centre differences in persistent ductus arteriosus treatment: can we improve outcome?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benchmarking; Cardiac Surgical Procedures; Ductus Arteriosu | 2017 |
Reopening of the ductus arteriosus in preterm infants; Clinical aspects and subsequent consequences.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Ductus Arteriosus; Ductus | 2018 |
Exploration of potential biochemical markers for persistence of patent ductus arteriosus in preterm infants at 22-27 weeks' gestation.
Topics: Biomarkers; Chemokine CCL2; Ductus Arteriosus, Patent; Echocardiography; Growth Differentiation Fact | 2019 |
Does Postmenstrual Age Affect Medical Patent Ductus Arteriosus Treatment Success in Preterm Infants?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; | 2019 |
Useful Platelet Indices for the Diagnosis and Follow-Up of Patent Ductus Arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Cell Count; Case-Control Studies; Drug Resistance; Du | 2019 |
Vascular endothelial growth factor polymorphism rs2010963 status does not affect patent ductus arteriosus incidence or cyclooxygenase inhibitor treatment success in preterm infants.
Topics: Case-Control Studies; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofe | 2019 |
Renal and mesenteric tissue oxygenation in preterm infants treated with oral ibuprofen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Gestational Age; Hemodynamics; H | 2014 |
Risk factors of mild rectal bleeding in very low birth weight infants: a case control study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Feces; Female; Gastrointestina | 2013 |
Variation and comparative effectiveness of patent ductus arteriosus pharmacotherapy in extremely low birth weight infants.
Topics: Cohort Studies; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Ind | 2014 |
[Clinical characteristics and cardiac hemodynamic changes of patent ductus ateriosus in preterm infants].
Topics: Birth Weight; Bronchopulmonary Dysplasia; Cardiac Output; Cyclooxygenase Inhibitors; Ductus Arterios | 2015 |
Neurodevelopmental Outcome at 2 Years of Age according to Patent Ductus Arteriosus Management in Very Preterm Infants.
Topics: Child, Preschool; Cohort Studies; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibup | 2016 |
Editorial: Patent Ductus Arteriosus in Extremely Premature Neonates.
Topics: Anterior Cerebral Artery; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echocardiography, Do | 2016 |
Oral ibuprofen for patent ductus arteriosus closure in preterm infants: does high osmolality matter?
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ib | 2008 |
[First SIBEN clinical consensus: diagnostic and therapeutic approach to patent ductus arteriosus in premature newborns].
Topics: Age Factors; Brain Diseases; Cost-Benefit Analysis; Cyclooxygenase Inhibitors; Diuretics; Ductus Art | 2008 |
Does Ibuprofen increase neonatal hyperbilirubinemia?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bilirubin; Cohort Studies; Ductus Arteriosus, Patent; Femal | 2009 |
A second course of ibuprofen is effective in the closure of a clinically significant PDA in ELBW infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Creatinine; Dose-Response Relationship, Dru | 2009 |
Isoprostane levels in urine of preterm newborns treated with ibuprofen for patent ductus arteriosus closure.
Topics: Antioxidants; Ductus Arteriosus, Patent; Female; Free Radicals; Humans; Ibuprofen; Infant, Newborn; | 2011 |
Effect of ibuprofen on bilirubin-albumin binding affinity in premature infants.
Topics: Albumins; Bilirubin; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Hyperbili | 2011 |
Aminoterminal B-type natriuretic peptide (NT-proBNP) in the therapy of patent ductus arteriosus.
Topics: Biomarkers; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Ibuprofen; Infant, Extremely | 2010 |
Urinary aquaporin-2 excretion during ibuprofen or indomethacin treatment in preterm infants with patent ductus arteriosus.
Topics: Aquaporin 2; Cardiovascular Agents; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Ibup | 2011 |
Patent ductus arteriosus in the preterm infant: a survey of clinical practices in French neonatal intensive care units.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Contraindications; Data Collection; Dose-Response Relations | 2011 |
The effects of ibuprofen on sepsis parameters in preterm neonates.
Topics: Anti-Inflammatory Agents, Non-Steroidal; C-Reactive Protein; Case-Control Studies; Ductus Arteriosus | 2012 |
Update on management of patent ductus arteriosus in the preterm infant.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; | 2011 |
Ibuprofen lysinate and sodium ibuprofen for prophylaxis of patent ductus arteriosus in preterm neonates.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Newborn; Infant, Pr | 2012 |
Oral ibuprofen for the treatment of patent ductus arteriosus: further clarification.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant, Premature, Diseases | 2012 |
Pharmacokinetics of oral ibuprofen for patent ductus arteriosus closure in preterm infants.
Topics: Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infan | 2012 |
Failure of a repeat course of cyclooxygenase inhibitor to close a PDA is a risk factor for developing chronic lung disease in ELBW infants.
Topics: Chronic Disease; Cyclooxygenase Inhibitors; Drug Administration Schedule; Ductus Arteriosus, Patent; | 2012 |
Does treatment of patent ductus arteriosus with cyclooxygenase inhibitors affect neonatal regional tissue oxygenation?
Topics: Analysis of Variance; Blood Gas Analysis; Cerebrovascular Circulation; Chi-Square Distribution; Chro | 2012 |
Severe pulmonary hypertension with therapeutic L-lysine ibuprofen in 2 preterm neonates.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diseases in Twins; Ductus Arteriosus, Patent; Echocardiogra | 2012 |
Early treatment of the patent ductus arteriosus: do we know what we are doing?.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Echocardiography, Doppler, Color | 2012 |
An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Contraindications; Drug Resistance; Ductus Arteriosus, Pate | 2013 |
An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Contraindications; Drug Resistance; Ductus Arteriosus, Pate | 2013 |
An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Contraindications; Drug Resistance; Ductus Arteriosus, Pate | 2013 |
An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Contraindications; Drug Resistance; Ductus Arteriosus, Pate | 2013 |
An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Contraindications; Drug Resistance; Ductus Arteriosus, Pate | 2013 |
An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Contraindications; Drug Resistance; Ductus Arteriosus, Pate | 2013 |
An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Contraindications; Drug Resistance; Ductus Arteriosus, Pate | 2013 |
An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Contraindications; Drug Resistance; Ductus Arteriosus, Pate | 2013 |
An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Contraindications; Drug Resistance; Ductus Arteriosus, Pate | 2013 |
Pulmonary hypertension in an infant treated with ibuprofen.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Hypertension, Pulmonary; Ibuprofen; In | 2013 |
Repeated courses of ibuprofen are effective in closure of a patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Drug Administration Schedule; Ductus Arteriosus, Patent; Female; Humans; | 2012 |
Effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus in preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Fema | 2013 |
Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants.
Topics: Ductus Arteriosus, Patent; Humans; Hypertension, Pulmonary; Ibuprofen; Infant, Newborn; Infant, Prem | 2002 |
Safety and efficacy of ibuprofen versus indomethacin in preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Infant, P | 2003 |
Urinary ET-1, AVP and sodium in premature infants treated with indomethacin and ibuprofen for patent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arginine Vasopressin; Cyclooxygenase 2 Inhibitors; Ductus A | 2005 |
Consequences of delayed surgical closure of patent ductus arteriosus in very premature infants.
Topics: Combined Modality Therapy; Ductus Arteriosus, Patent; Enteral Nutrition; Female; Gestational Age; Hu | 2006 |
Pulmonary hypertension following L-lysine ibuprofen therapy in a preterm infant with patent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Fatal Outcome; Humans; Hypertens | 2006 |
Conservative treatment for patent ductus arteriosus in the preterm.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Femal | 2007 |
Oral ibuprofen in early curative closure of patent ductus arteriosus in very premature infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Echocardiography, Doppler, Color | 2007 |
Ibuprofen treatment of patent ductus arteriosus.
Topics: Brain; Cerebrovascular Circulation; Ductus Arteriosus, Patent; Gestational Age; Humans; Ibuprofen; I | 1995 |
Cerebral vasoreactivity to arterial carbon dioxide tension in preterm infants: the effect of ibuprofen.
Topics: Brain; Carbon Dioxide; Cerebrovascular Circulation; Ductus Arteriosus, Patent; Hemoglobins; Humans; | 1999 |
Ibuprofen and patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newbo | 2000 |
Ibuprofen versus indomethacin for closure of patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newbo | 2001 |
Ibuprofen-lysine for closure of patent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Combinations; Ductus Arteriosus, Patent; Humans; Ibupr | 2001 |